$34.710
-2.652 (-7.64%)At close
ROIV News
ROIV Events
Priovant Therapeutics Receives FDA Approval for Lisraya to Treat Dermatomyositis
Priovant Therapeutics announced that the U.S. FDA has approved Lisraya 30 mg for the treatment of adults with dermatomyositis. Lisraya is a pill taken once daily. Priovant Therapeutics is a Roivant company.
Roivant Reports Q1 Revenue of $1.44M, Below Consensus
Reports Q1 revenue $1.44M, consensus $2.34M. "This quarter has been a moment of relative quiet between our incredibly busy last twelve months and our even busier year ahead," said Matt Gline, CEO of Roivant. "Our teams are deep in preparation for the potential launch of brepocitinib in dermatomyositis, we have enrolled the first patients in a new Phase 3 trial in cutaneous sarcoidosis, and we expect topline readouts from our NIU, PH-ILD and CLE studies before year end. We remain focused on delivering for patients across each of these programs, and if we are successful across even some of these endeavors, we will look radically different on the other side."
Arbutus Files Lawsuits to Protect LNP Technology Patents
Arbutus Biopharma (ABUS) and its exclusive licensee, Genevant Sciences, a subsidiary of Roivant (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer (PFE), BioNTech (BNTX) and certain of their affiliates. Arbutus and Genevant are seeking monetary relief, as well as injunctions against Pfizer/BioNTech's mRNA-LNP COVID-19 vaccines and any other products that would infringe the asserted patents. The UPC actions seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, and Sweden. These actions expand on Arbutus and Genevant's ongoing enforcement proceeding in the U.S. District Court for the District of New Jersey, seeking fair compensation for Pfizer/BioNTech's infringement of five U.S. patents in the manufacture and sale of Pfizer/BioNTech's mRNA-LNP COVID-19 vaccines.
Major Averages Close Broadly Higher as Oil Prices Slip Below $100
The major averages closed broadly higher, cutting into this week's previous losses as oil prices slipped to below $100 per barrel. Semiconductor stocks rebounded after several sessions dominated by rising yields and inflation fears, with the market fully focused on tonight's highly anticipated Nvidia earnings report.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Targetreportedand reiterated its FY26 outlookLowe'sreportedand backed its FY26 guidanceTJXprovided areport for Q1Hasbroreportedand provided its outlook for FY26Intuitwill streamline operations, including laying off 17% of its staff,2. WALL STREET CALLS:Etsyto Buy from Neutral at AreteNorthlandXponential Fitnesson potential for near-term dealOppenheimerRubrikto Outperform on sector, product strengthPhreesiato Equal Weight at Wells FargoCignato Hold at Deutsche Bank3. AROUND THE WEB:Paramount Skydanceis aiming to finalize its takeover of Warner Bros. Discoveryas soon as July, NY Post reportsPepsiCoplans to increase to increase prices on some of its smaller bags of chips by 10c-20c, Bloomberg saysGoogleDeepMind has agreed to hire more than 20 researchers from AI startup Contextual AI and license its technology in a deal valued at approximately $100M, including the addition of co-founder and CEO Douwe Kiela to the DeepMind team, Bloomberg reportsIntelis asking its leading PC partners, including those in the U.S., China, and Taiwan, to use more 18A CPUs, citing better supply than chips on older nodes, Nikkei Asia saysNvidiahas committed $90B to dealmaking in the AI industry over the past 16 months, FT says4. MOVERS:Roivant Scienceshigher after, with EPS beating consensusImmunityBioincreases after the FDA accepted aMedlinefalls afterMayville Envineeringlower after announcing aGDS Holdingsand Kanzhundecline after5. EARNINGS/GUIDANCE:VF Corp., with EPS and revenue beating consensusAnalog Devices, with CEO Vincent Roche commenting, "ADI's second quarter revenue and earnings were above the high end of our outlook"James Hardie, with CEO James Hardie commenting, "We delivered Adjusted EBITDA above our guidance range in the fourth quarter, reflecting disciplined execution and the strength of our business model"Red Robinand reaffirmed guidance for FY26Cava Group, with EPS and revenue beating consensusINDEXES:The Dow rose 645.47, or 1.31%, to 50,009.35, the Nasdaq gained 399.65, or 1.54%, to 26,270.36, and the S&P 500 advanced 79.36, or 1.08%, to 7,432.97.
Roivant Sciences Stock Rises 15.2% to $32.49
Roivant Sciences is up 15.2%, or $4.28 to $32.49.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.